Private Insurance

;
Ensuring copay assistance counts for patients: Litigation update

Ensuring copay assistance counts for patients: Litigation update

Oct 14, 2022

At Informa Connect’s Copay, Reimbursement and Access Congress, Carl Schmid discusses the litigation filed by HIV+Hep, the DLC, and the DPAC in the U.S. District Court for DC challenging a federal rule that allows health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations in violation of the ACA definition of and regulations for cost-sharing.

read more

Press briefing on HIV+Hep, DLC, and DPAC vs. HHS

Aug 30, 2022

The HIV+Hepatitis Policy Insite, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition filed suit in the U.S. District Court for the District of Columbia challenging a federal rule that allows health insurers and pharmacy benefits managers to avoid counting drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. Due to increased deductibles and cost-sharing requirements, patients rely on copay assistance to help them afford their medications.

read more
Plan benefit design, prescription drugs, and race

Plan benefit design, prescription drugs, and race

Aug 23, 2022

Carl Schmid presents to NAIC Special Committee on Race & Insurance on how insurance benefit design impacts prescription drug access for racial and ethnic communities and suggestions for overcoming access barriers by reducing utilization management measures, lowering cost-sharing, offering standardized plans, and enforcing ACA non-discrimination policies.

read more
Importance of copay assistance in patient affordability of prescription drugs

Importance of copay assistance in patient affordability of prescription drugs

May 17, 2022

Copay assistance provides a safety net to help patients afford and adhere to medically-necessary medications. But, the Centers for Medicare & Medicaid Services (CMS) Best Price Rule, finalized by the Trump administration in 2020, threatens patient access to these critical programs. If implemented, the final rule would allow insurers and pharmacy benefit managers (PBMs) to undermine copay assistance through copay accumulator adjustment programs that block patient assistance from counting towards a patient’s deductible and out-of-pocket cost-sharing requirements. Watch this virtual briefing to learn about the value of patient copay assistance programs and how you can get engaged to protect communities from the unintended consequences of the CMS Best Price Rule.

read more

Search

Tags

ACA Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing Drug Pricing healthcare Hepatitis Hepatitis B Hepatitis C HIV HIV Prevention Insurers Medicaid NAIC PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state Testing transparency Treatment Trump administration

Recent Presentations

Pin It on Pinterest